Compare · JANX vs NVS
JANX vs NVS
Side-by-side comparison of Janux Therapeutics Inc. (JANX) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JANX and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 295.9x JANX ($991.6M).
- Over the past year, JANX is down 37.7% and NVS is up 34.7% - NVS leads by 72.4 points.
- JANX has hit the wire 1 time in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 19 for JANX).
- Company
- Janux Therapeutics Inc.
- Novartis AG
- Price
- $16.26+2.68%
- $153.72+0.64%
- Market cap
- $991.6M
- $293.40B
- 1M return
- +18.77%
- +1.89%
- 1Y return
- -37.70%
- +34.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 0
- Recent ratings
- 19
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest JANX
- President and CEO Campbell David Alan exercised 7,000 shares at a strike of $4.21, increasing direct ownership by 2% to 388,582 units (SEC Form 4)
- Janux Therapeutics Inc. filed SEC Form 8-K: Other Events
- Director Ra Capital Management, L.P. was granted 5,500 shares (SEC Form 4)
- Director Simson Jake was granted 5,500 shares (SEC Form 4)
- Director Hernday Natasha was granted 5,500 shares, increasing direct ownership by 55% to 15,481 units (SEC Form 4)
- Director Kung Winston was granted 5,500 shares, increasing direct ownership by 88% to 11,750 units (SEC Form 4)
- Director Capps Vickie L was granted 5,500 shares, increasing direct ownership by 7% to 79,598 units (SEC Form 4)
- Director Barrett Ronald W was granted 5,500 shares, increasing direct ownership by 88% to 11,750 units (SEC Form 4)
- Director Dobmeier Eric was granted 5,500 shares, increasing direct ownership by 55% to 15,481 units (SEC Form 4)
- Janux Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG